Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study.

Manika K, Chatzika K, Papaioannou M, Kontou P, Boutou A, Zarogoulidis K, Kioumis I.

Int J Tuberc Lung Dis. 2015 Nov;19(11):1383-7. doi: 10.5588/ijtld.14.0935.

PMID:
26467592
2.

Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment.

van den Boogaard J, Semvua HH, Boeree MJ, Aarnoutse RE, Kibiki GS.

J Antimicrob Chemother. 2010 Jan;65(1):145-7. doi: 10.1093/jac/dkp413.

PMID:
19900951
3.

Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.

Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T.

Clin Infect Dis. 2009 May 15;48(10):1354-60. doi: 10.1086/598196.

PMID:
19348594
4.

Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.

Gaba PD, Haley C, Griffin MR, Mitchel E, Warkentin J, Holt E, Baggett P, Sterling TR.

Arch Intern Med. 2007 Nov 26;167(21):2317-22.

PMID:
18039990
5.

[Antibiotic sensitivity of pathogenic microflora: data of the bacteriological laboratory at the antituberculosis clinic].

Vizel' AA, Ozol SM, Guryleva ME, Gizatullina ED.

Probl Tuberk. 1998;(4):48-51. Russian.

PMID:
9771042

Supplemental Content

Loading ...
Support Center